At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 110 target
Drug / intervention
XKH002 Injectiondrug
Likely dose
XKH002 Injection 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, First-in-human (FIH),Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of XKH002 in Patients With Advanced or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating XKH002 Injection for Advanced or Metastatic Solid Tumors. Targeting 110 participants across 1 site.
Detailed Summary
This is a Phase 1, first-in-human (FIH), open-label, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of XKH002 in patients with advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Metastatic Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202420252026
Enrollment StartNov 2023
First PostedJan 2024
Primary CompletionDec 2025
Study CompletionApr 2026
TodayJul 2026
First PostedJan 9, 2024
Enrollment StartNov 27, 2023
Primary CompletionDec 1, 2025
Study CompletionApr 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 2.5 years ago
Interventions
XKH002 Injectiondrug
240 mg/4 mL/vial（60 mg/mL）